GSK
Stock Details
GSK is GSK plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 35.95$. Average daily volumn in 3 months 6.52M. Market cap 60.25B
Stock symbol : GSK. Exchange : NYSE. Currency : USD Lastest price : 29.36$. Total volume : 9.04M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
GSK plc (GSK)
Last Price
29.36$Change
-0.65Volume
9.04M
| Previous Close | 30.01 |
| Open | 29.45 |
| Day Range | 29.09-29.63 |
| Bid | 29.45 x 1.1k |
| Ask | 29.65 x 2.2k |
| Volume | 9.04M |
| Average Volume | 6.52M |
| Market Cap | 60.25B |
| Beta | 0.26 |
| 52 Week Range | 29.09-46.97 |
| Trailing P/E | 11.29 |
| Foward P/E | 8.39 |
| Dividend (Yield %) | 8.34% |
| Ex-Dividend Date | 2022-05-19 |
Financial Details
Organization
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory... , HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Market Cap:
60.25BRevenue:
34.11BTotal Assets:
79.1BTotal Cash:
4.27B
News about "GSK plc"
GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News
Source from : YAHOO!Finance - 8 hours ago
British drugmaker GSK plc, has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday. GSK could announce as soon as Monday morning ...See details»
Transcend Capital Advisors LLC Trims Position in GSK plc (NYSE:GSK)
Source from : Defense World - 2 days ago
Transcend Capital Advisors LLC decreased its holdings in shares of GSK plc (NYSE:GSK – Get Rating) by 9.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned ...See details»
GSK picks up troubled Spero drug for nearly $300M, takes stake in company
Source from : The Business Journals - 2 days ago
Less than five months after discouraging conversations with the U.S. Food and Drug Administration led Spero Therapeutics Inc. to pause work on a drug and lay off 110 people, the company is licensing ...See details»
GSK announces USFDA committee to review Zejula overall survival data from NOVA phase III trial in recurrent ovarian cancer
Source from : Daily - 13 hours ago
UK: GSK plc has announced that the US Food and Drug Administration (USFDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss overall survival (OS) data from ...See details»
Brookstone Capital Management Boosts Stock Position in GSK plc (NYSE:GSK)
Source from : Defense World - 3 days ago
Brookstone Capital Management raised its position in shares of GSK plc (NYSE:GSK – Get Rating) by 147.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The ...See details»
Spero signs $600M license deal for UTI antibiotic with GSK – three months after FDA rejected it
Source from : BioWorld - 2 days ago
Spero Therapeutics Inc. has come out swinging after a U.S. FDA rejection for its oral antibiotic, tebipenem Hbr, picking up a potential $600 million licensing deal with pharma giant GSK plc after ...See details»
GSK plc: Diving Into the Drug Pricing Hit From the Inflation Reduction Act, We’ve Reduced Our FVEs by 2%
Source from : Yahoo Finance - 5 days ago
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral ...See details»
GSK, Regeneron Covid Antibody Drugs Unlikely to Work for Omicron, WHO Says
Source from : Bloomberg L.P. - 9 days ago
The antibody drugs GSK Plc and Regeneron Pharmaceuticals Inc. developed against Covid don’t appear to work for omicron and its subvariants, a panel of experts advising the World Health Organization ...See details»
GSK Secures Urinary Tract Infections Treatment License With Spero Therapeutics
Source from : MarketWatch - 2 days ago
By Michael Susin GSK PLC said Thursday that it has signed an exclusive license agreement with Spero Therapeutics Inc. to commercialize tebipenem HBr, ...See details»
GSK To Receive Licence From Spero To Develop, Commercialise Tebipenem Pivoxil HBr
Source from : Business Insider - 2 days ago
GSK plc (GSK, GSK.L) and Spero Therapeutics, Inc. (SPRO) have entered into a licence agreement for tebipenem pivoxil hydrobromide or ...See details»
GSK 'sell' rating removed by Credit Suisse as Zantac liabilities expected to be US$5bn
Source from : Proactiveinvestors - 9 days ago
The overhang from the cancer lawsuits are expected to linger, but the US$12bn wiped off its market cap “is much higher than what we might expect to be GSK’s share of any settlement” GSK PLC (LSE:GSK, ...See details»
Glaxosmithkline plc - ADR Shares Approach 52-Week Low - Market Mover
Source from : Nasdaq - 6 days ago
Glaxosmithkline plc - ADR shares closed today at 1.0% above its 52 week low of $30.49, giving the company a market cap of $62B. The stock is currently down 42.2% year-to-date, dow ...See details»
TOP NEWS: GSK signs licence deal for Spero's tebipenem HBr antibiotic
Source from : London South East - 2 days ago
GSK PLC on Thursday said it has signed an exclusive licence agreement with Massachusetts-based biotechnology firm Spero Therapeutics for the latter's tebipenem pivoxil hydrobromide, or tebipenem HBr.See details»
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Source from : Yahoo! Sports - 5 days ago
Theravance Biopharma Inc (NASDAQ: TBPH) is buying back over 9.6 million shares from GSK plc (NYSE: GSK) for roughly $94 million, according to an SEC filing. In addition, Theravance plans to buy back ...See details»